Scientific Advisory Board

Prof. Nina Bhardwaj, MD

Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City; elected member of the American Society of Clinical Investigation and the American Association of Physicians; senior editor of the AACR Cancer Immunology Research journal

Ralf Clemens, MD, Chair of the SAB

former Vice President/ Senior Vice President GSK Biologicals, Novartis Vaccines and Takeda Vaccines; advisor to the Bill & Melinda Gates Foundation and to the Africa Research Excellence Fund (AREF); member of CureVac’s Supervisory Board

Michel De Wilde, PhD

member of the Board of Directors of the Infectious Disease Research Institute (IDRI) and of VBI; former Senior Vice President R&D at Sanofi Pasteur and Vice President Research GSK Biologicals

Prof. Dirk Jäger, MD

Director of Medical Oncology at the University Hospital of Heidelberg, Germany; leader of the research group “Applied Tumor Immunity” at the German Cancer Research Center

Prof. Karim Fizazi, MD

Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France; President of the French Study Group of Carcinomas of Unknown Primary and associate editor of the European Journal of Cancer

Christopher Karp, MD

Director of Global Health Discovery & Translational Sciences at the Bill & Melinda Gates Foundation

Prof. Michael P. Manns, MD

Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Germany

Prof. Stanley Plotkin, MD

Emeritus Professor of the Wistar Institute and the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University; editor of the standard textbook “Vaccines”

Jean-Paul Prieels, PhD

Member of the Board of various Biotech companies including DNAlytics and Vaximm; former Senior Vice President R&D at GlaxoSmithKline Biologicals

Prof. Hans-Georg Rammensee, PhD

Head of the Department of Immunology at the University of Tübingen, Germany

George R Siber, MD

Chief Scientific Officer, ClearPath Vaccines Company and former Executive Vice President of Wyeth Pharma, CSO of Wyeth Vaccines and Director of the Massachusetts Biologic Laboratories

Prof. Daniel Speiser, MD

head of clinical tumor biology and immunotherapy group, Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, Switzerland

Prof. Xiao-Ning Xu, MD, PhD

Chair in Human Immunology at the Imperial College London; previously Head of Novartis Vaccines Research China

Prof. Fred Zepp, MD

Medical Director and Chairman of the Department of Pediatrics, University Medical Center of the Johannes Gutenberg-University Mainz, Germany; past president of the German Society of Pediatrics and Adolescent Medicine; member of the STIKO at the Robert Koch Institute

Gerd Zettlmeissl, PhD

Chairman Hilleman Laboratories, Board of Directors of Aeras and board member of various Biotech companies; former Managing Director of Chiron Behring and Chief Executive Officer of Intercell